HealthMyne, a Madison, Wis.-based provider of a platform bringing multiple enhanced clinical decision support (CDS) workflow modules to Radiology and the Oncology care continuum, raised $15M in Series B funding.
The round was led by Ascension Ventures, with participation from existing institutional backers Venture Investors, 4490 Ventures, and WARF.
The company intends to use the funds to expand its global commercialization efforts.
Led by Arvind Subramanian, President & CEO, HealthMyne provides a FDA-cleared software Quantitative Imaging Decision Support (QIDS®) platform for Radiology and Oncology to U.S.-based multi-hospital systems.
The platform’s novel Rapid Precise Metrics (RPM)™ algorithms deliver Point-of-Read image-derived curated metrics integrated with other clinical systems data (e.g. PACS, EMR, RT) into multiple Point-of-Care workflow modules to ensure timely clinical decision support (CDS) and precise patient management.
The platform provides patient-centric reports and an integrated clinical and imaging dashboard to optimize collaboration among the multidisciplinary care team. Additionally, its discoverable database supports data mining and AI-based application development for Precision Medicine/Big Data initiatives and for innovative clinical, translational, and commercial research by both medical centers and pharmaceutical/biotech companies.
Workflow modules include Cancer Screening, Tumor Board Management, Clinical Trials/Therapy Response Assessment, Incidental Findings, Thoracic Specialty, others.